Vaccine Advisory Panel to Decide on Use of Mercury-Based Preservative
A revamped government vaccine advisory panel, appointed by Health and Human Services Secretary Robert F. Kennedy Jr., is set to deliberate on the use of a mercury-containing preservative in flu vaccines. This preservative, known as thimerosal, has faced controversy due to past, unfounded claims linking it to autism, despite robust scientific evidence disproving such a connection.
What’s on the Agenda for June 26?
The Advisory Committee on Immunization Practices (ACIP) will meet on June 26 to hear a detailed presentation about thimerosal followed by a vote on recommendations regarding vaccines containing this preservative. This marks the first gathering of ACIP with Kennedy’s newly appointed members, several of whom have publicly expressed skepticism toward vaccines.
Understanding Thimerosal and Its Use in Vaccines
Thimerosal serves as an antimicrobial preservative in various multi-dose vaccines to prevent bacterial contamination. While its use has declined sharply as manufacturers increasingly adopt single-dose vials that require no preservatives, approximately half of the flu vaccines for adults in the U.S. still contain trace amounts of thimerosal. Examples include the well-known Fluzone and certain formulations from biotech company CSL Seqirus.
Importantly, all vaccines routinely recommended for children under six years old are available in thimerosal-free formulations, ensuring safety in pediatric immunizations.
Science Confirms the Safety of Thimerosal
Over two decades of rigorous studies have consistently shown no evidence linking thimerosal in vaccines to autism or other serious health effects. Public health authorities like the Food and Drug Administration emphasize that extensive research supports the preservative’s safety profile.
“The scientific evidence collected over the past 20+ years does not show any evidence of harm, including serious neurodevelopmental disorders, from use of thimerosal in vaccines,” states the FDA.
Significance of the New ACIP Panel
The makeup of ACIP has shifted substantially under Kennedy’s leadership, with eight newly appointed members replacing much of the previous committee. Their votes will influence national immunization policies, including which vaccines are recommended and covered by insurance programs.
Besides thimerosal, the committee will also review and vote on other important vaccines during the two-day session, including those targeting Covid-19 and RSV.
Looking Ahead
The upcoming decisions will be closely watched, especially as public debate surrounding vaccine safety continues. With new advisors holding divergent views, the ACIP’s recommendations could shape the direction of U.S. vaccination strategies in the years to come.
